BUZZ-Biocryst Pharmaceuticals Inc: Ebola outbreak garners interest

Fri Aug 8, 2014 9:30am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's shares up 3.8 pct at $13.40 premarket

** Ebola outbreak has significantly increased visibility Biocryst's experimental broad spectrum antiviral, BCX4430

** Although current focus for BCX4430 is against Marburg virus, we see future development against Ebola - Brinson Patrick analyst Christopher James

** With ongoing Ebola outbreak garnering interest in BCX4430's further study, we believe government-driven stockpiling market opportunity is emerging - MLV & Co analyst Vernon Bernardino

** Canadian drugmaker Tekmira Pharmaceuticals Corp's U.S.-listed shares up 18.5 pct premarket

** FDA said Thursday it modified clinical hold on Tekmira's experimental Ebola drug from "full" to "partial" to enable potential use in people infected with the virus

** Sarepta Therapeutics Inc shares up 3 pct, NanoViricides Inc up 9 pct premarket; Both companies developing ebola treatments